The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Novel Role for the AnxA1-Fpr2/ALX Signaling Axis as a Key Regulator of Platelet Function to Promote Resolution of Inflammation
Open accessAbstract
Background: Ischemia reperfusion injury (I/RI) is a common complication of cardiovascular diseases. Resolution of detrimental I/RI-generated prothrombotic and proinflammatory responses is essential to restore homeostasis. Platelets play a crucial part in the integration of thrombosis and inflammation. Their role as participants in the resolution of thromboinflammation is underappreciated; therefore we used pharmacological and genetic approaches, coupled with murine and clinical samples, to uncover key concepts underlying this role. Methods: Middle cerebral artery occlusion with reperfusion was performed in wild-type or annexin A1 (AnxA1) knockout (AnxA1 −/− ) mice. Fluorescence intravital microscopy was used to visualize cellular trafficking and to monitor light/dye–induced thrombosis. The mice were treated with vehicle, AnxA1 (3.3 mg/kg), WRW4 (1.8 mg/kg), or all 3, and the effect of AnxA1 was determined in vivo and in vitro. Results: Intravital microscopy revealed heightened platelet adherence and aggregate formation post I/RI, which were further exacerbated in AnxA1 −/− mice. AnxA1 administration regulated platelet function directly (eg, via reducing thromboxane B 2 and modulating phosphatidylserine expression) to promote cerebral protection post-I/RI and act as an effective preventative strategy for stroke by reducing platelet activation, aggregate formation, and cerebral thrombosis, a prerequisite for ischemic stroke. To translate these findings into a clinical setting, we show that AnxA1 plasma levels are reduced in human and murine stroke and that AnxA1 is able to act on human platelets, suppressing classic thrombin-induced inside-out signaling events (eg, Akt activation, intracellular calcium release, and Ras-associated protein 1 [Rap1] expression) to decrease α IIb β 3 activation without altering its surface expression. AnxA1 also selectively modifies cell surface determinants (eg, phosphatidylserine) to promote platelet phagocytosis by neutrophils, thereby driving active resolution. (n=5–13 mice/group or 7–10 humans/group.) Conclusions: AnxA1 affords protection by altering the platelet phenotype in cerebral I/RI from propathogenic to regulatory and reducing the propensity for platelets to aggregate and cause thrombosis by affecting integrin (α IIb β 3 ) activation, a previously unknown phenomenon. Thus, our data reveal a novel multifaceted role for AnxA1 to act both as a therapeutic and a prophylactic drug via its ability to promote endogenous proresolving, antithromboinflammatory circuits in cerebral I/RI. Collectively, these results further advance our knowledge and understanding in the field of platelet and resolution biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932 · cited 1×
“7,9,37,38 Although recent interest has been dedicated to effects of AnxA1 with respect to leukocytes (neutrophils, macrophages) in inflammation resolution, the role that platelets (which express Fpr2/ALX [Figure VI in the on-line-only Data Supplement], the key receptor involved in the resolution…”
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Ischaemic stroke: a thrombo‐inflammatory disease?
Nieswandt, B., Kleinschnitz, C., & Stoll, G. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.212886 · Cited by 192
Cited by
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity
Hirao, H., Nakamura, K., & Kupiec-Weglinski, J. W. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00549-8 · Cited by 364
Xu, X., Gao, W., Li, L., Hao, J., Yang, B., Wang, T., Li, L., Bai, X., Li, F., Ren, H., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02174-3 · Cited by 274
Das, D., Shruthi, N. R., Banerjee, A., Jothimani, G., Duttaroy, A. K., & Pathak, S. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1221438 · Cited by 90
“The overall effect of these anomalies is increased platelet adhesion and activation (152).”
Background
Metadata
- Authors
- Senchenkova, E. Y., Ansari, J., Becker, F., Vital, S. A., Al-Yafeai, Z., Sparkenbaugh, E. M., Pawlinski, R., Stokes, K. Y., Carroll, J. L., Dragoi, A.-M., Qin, C. X., Ritchie, R. H., Sun, H., Cuellar-Saenz, H. H., Rubinstein, M. R., Han, Y. W., Orr, A. W., Perretti, M., Granger, D. N., & Gavins, F. N. E.
- Venue
- Circulation
- Published
- 2019-07-23
- Volume
- 140
- Issue
- 4
- Pages
- 319-335
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2948033422
- Cited by
- 160
- References
- 4
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.